Efficacy of everolimus plus hormonal treatment after cyclin-dependent kinase inhibitor; real-life experience, A TOG study.

IF 3 3区 医学 Q2 ONCOLOGY Breast Cancer Research and Treatment Pub Date : 2024-12-01 Epub Date: 2024-08-09 DOI:10.1007/s10549-024-07456-x
İsmail Beypınar, Hacer Demir, Şendağ Yaslıkaya, Tolga Köşeci, Bilgin Demir, Gökhan Çolak, Ahmet Burak Ağaoğlu, Mustafa Şahbazlar, Pervin Can Şancı, Devrim Çabuk, Ulaş Işık, Elif Şahin, Alper Coşkun, Burcu Caner, Talat Aykut, Mehmet Artaç, Mustafa Emre Duygulu, Nadiye Sever, Sıla Öksüz, Nedim Turan, Musa Barış Aykan, Esmanur Kaplan Tüzün, Mükremin Uysal, İrem Uğurlu, Abdullah Sakin, Caner Acar, Duygu Özaşkın, Teoman Şakalar, Merve Keskinkılıç, Tuğba Yavuzşen, Naziyet Köse, İsmail Ertürk, Nilgün Yıldırım, Onur Yazdan Balçık, Ali Alkan, Oğuzhan Selvi, Eda Erçin, Olçun Ümit Ünal, Cengiz Karaçin
{"title":"Efficacy of everolimus plus hormonal treatment after cyclin-dependent kinase inhibitor; real-life experience, A TOG study.","authors":"İsmail Beypınar, Hacer Demir, Şendağ Yaslıkaya, Tolga Köşeci, Bilgin Demir, Gökhan Çolak, Ahmet Burak Ağaoğlu, Mustafa Şahbazlar, Pervin Can Şancı, Devrim Çabuk, Ulaş Işık, Elif Şahin, Alper Coşkun, Burcu Caner, Talat Aykut, Mehmet Artaç, Mustafa Emre Duygulu, Nadiye Sever, Sıla Öksüz, Nedim Turan, Musa Barış Aykan, Esmanur Kaplan Tüzün, Mükremin Uysal, İrem Uğurlu, Abdullah Sakin, Caner Acar, Duygu Özaşkın, Teoman Şakalar, Merve Keskinkılıç, Tuğba Yavuzşen, Naziyet Köse, İsmail Ertürk, Nilgün Yıldırım, Onur Yazdan Balçık, Ali Alkan, Oğuzhan Selvi, Eda Erçin, Olçun Ümit Ünal, Cengiz Karaçin","doi":"10.1007/s10549-024-07456-x","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>In advanced breast cancer, endocrine therapy is preferred in the absence of visceral crisis. Cyclin-dependent kinase inhibitors (CDKi) are the gold standards. The selection of subsequent treatments after CDKi treatment is still controversial, and the efficacy of everolimus (EVE) combinations is unknown. In this study, we aimed to investigate the efficacy of EVE after CDKi administration in real-life experiences.</p><p><strong>Method: </strong>The study received data from 208 patients from 26 cancer centers. Demographic and histologic features, diagnosis, progression, last visit dates, and toxicities were recorded. This study was a retrospective case series.</p><p><strong>Results: </strong>One hundred and seven patients received palbociclib, while 101 patients received ribociclib as a CDKi. The overall response and disease control rates of EVE combinations were 60% and 88%, respectively. In univariate analysis, the absence of liver metastasis, age > 40 years, better type of response, and immediate treatment after CDKi were related to increased progression-free survival. Liver metastasis and response type were significantly associated with overall survival. In the multivariate analysis, response remained significant in terms of progression-free survival, while response type, liver metastatic disease, and hematologic toxicity were prognostic in terms of overall survival.</p><p><strong>Conclusion: </strong>This study provides evidence of the benefits of EVE combinations after CDKi treatment. EVE combinations may be more appropriate for patients with non-liver metastasis, and the first treatment response shows the benefit of treatment. In addition, immediate treatment after CDKi treatment is more beneficial than later lines of treatment.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"597-604"},"PeriodicalIF":3.0000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast Cancer Research and Treatment","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10549-024-07456-x","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/9 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: In advanced breast cancer, endocrine therapy is preferred in the absence of visceral crisis. Cyclin-dependent kinase inhibitors (CDKi) are the gold standards. The selection of subsequent treatments after CDKi treatment is still controversial, and the efficacy of everolimus (EVE) combinations is unknown. In this study, we aimed to investigate the efficacy of EVE after CDKi administration in real-life experiences.

Method: The study received data from 208 patients from 26 cancer centers. Demographic and histologic features, diagnosis, progression, last visit dates, and toxicities were recorded. This study was a retrospective case series.

Results: One hundred and seven patients received palbociclib, while 101 patients received ribociclib as a CDKi. The overall response and disease control rates of EVE combinations were 60% and 88%, respectively. In univariate analysis, the absence of liver metastasis, age > 40 years, better type of response, and immediate treatment after CDKi were related to increased progression-free survival. Liver metastasis and response type were significantly associated with overall survival. In the multivariate analysis, response remained significant in terms of progression-free survival, while response type, liver metastatic disease, and hematologic toxicity were prognostic in terms of overall survival.

Conclusion: This study provides evidence of the benefits of EVE combinations after CDKi treatment. EVE combinations may be more appropriate for patients with non-liver metastasis, and the first treatment response shows the benefit of treatment. In addition, immediate treatment after CDKi treatment is more beneficial than later lines of treatment.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
细胞周期蛋白依赖性激酶抑制剂后依维莫司加激素治疗的疗效;现实生活中的经验,一项TOG研究。
目的:对于晚期乳腺癌患者,如果没有内脏危机,内分泌治疗是首选。细胞周期蛋白依赖性激酶抑制剂(CDKi)是金标准。CDKi 治疗后后续治疗方法的选择仍存在争议,依维莫司(EVE)联合疗法的疗效尚不清楚。在这项研究中,我们旨在根据实际经验调查 CDKi 治疗后依维莫司(EVE)的疗效:研究收集了来自 26 个癌症中心的 208 名患者的数据。记录了患者的人口学和组织学特征、诊断、病情进展、最后就诊日期和毒性反应。本研究是一项回顾性病例系列研究:107 名患者接受了帕博西尼(palbociclib)治疗,101 名患者接受了作为 CDKi 的利博西尼(ribociclib)治疗。EVE组合的总体反应率和疾病控制率分别为60%和88%。在单变量分析中,无肝转移、年龄大于40岁、较好的反应类型以及CDKi后立即治疗与无进展生存期的延长有关。肝转移和反应类型与总生存期显著相关。在多变量分析中,反应对无进展生存期仍有重要影响,而反应类型、肝转移性疾病和血液毒性对总生存期有预后作用:结论:本研究为 CDKi 治疗后 EVE 联合用药的益处提供了证据。EVE联合疗法可能更适用于非肝转移患者,首次治疗反应显示了治疗的益处。此外,CDKi治疗后立即治疗比后期治疗更有益。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
6.80
自引率
2.60%
发文量
342
审稿时长
1 months
期刊介绍: Breast Cancer Research and Treatment provides the surgeon, radiotherapist, medical oncologist, endocrinologist, epidemiologist, immunologist or cell biologist investigating problems in breast cancer a single forum for communication. The journal creates a "market place" for breast cancer topics which cuts across all the usual lines of disciplines, providing a site for presenting pertinent investigations, and for discussing critical questions relevant to the entire field. It seeks to develop a new focus and new perspectives for all those concerned with breast cancer.
期刊最新文献
Correction: FBLN2 is associated with basal cell markers Krt14 and ITGB1 in mouse mammary epithelial cells and has a preferential expression in molecular subtypes of human breast cancer. A randomised trial comparing 6-monthly adjuvant zoledronate with a single one-time dose in patients with early breast cancer. Alterations in the expression of homologous recombination repair (HRR) genes in breast cancer tissues considering germline BRCA1/2 mutation status. Efficacy of antiobesity medications among breast cancer survivors taking aromatase inhibitors. Cost containment analysis of superparamagnetic iron oxide (SPIO) injection in patients with ductal carcinoma in situ.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1